文献速递衰弱、肌少症与跌倒老年慢病共病管理安宁疗护

衰弱与澳大利亚转移性癌症ICU患者长期生存的回顾性队列研究

Frailty and long-term survival among patients in Australian intensive care units with metastatic cancer (FRAIL-CANCER study): a retrospective registry-based cohort study.
PubMed 文献 · Lancet Healthy Longev · 2023-01-01

BACKGROUND: Recent advances in cancer therapeutics have improved outcomes, resulting in increasing candidacy of patients with metastatic cancer being admitted to intensive care units (ICUs).…

核心结论

  • 在转入ICU的转移性癌症患者中,衰弱与更差的长期生存相关。
  • 衰弱患者可能受益于ICU内目标一致的时间限制性试验及后续重症后支持管理。

研究设计与样本

  • 回顾性注册队列研究,使用澳大利亚与新西兰重症监护学会成人患者数据库。
  • 纳入2018年1月1日至2022年3月31日入住166个澳大利亚ICU、有临床衰弱量表(CFS)记录的晚期实体瘤或血液肿瘤患者。
  • 采用Cox比例风险回归模型with稳健三明治方差估计,评估衰弱对ICU入住后至多4年生存时间的影响。

关键数值与推荐

  • 衰弱定义为CFS 5-8。
  • 纳入患者年龄≥16岁。
  • 主要结局为ICU入住后至多4年的生存时间。

临床怎么用

  • 对转移性癌症ICU患者应评估衰弱状态(CFS),以辅助预后沟通与照护目标讨论。
  • 对衰弱患者可考虑目标一致的时间限制性ICU试验,并规划重症后支持管理。
  • 年轻衰弱患者效应更大,不应因年龄较轻而忽视衰弱评估。

局限性

  • 为回顾性注册研究设计,可能存在未测量混杂。
  • 仅纳入有CFS记录的患者,可能存在选择偏倚。
  • 数据来自澳大利亚ICU,外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Recent advances in cancer therapeutics have improved outcomes, resulting in increasing candidacy of patients with metastatic cancer being admitted to intensive care units (ICUs). A large proportion of patients also have frailty, predisposing them to poor outcomes, yet the literature reporting on this is scarce. We aimed to assess the impact of frailty on survival in patients with metastatic cancer admitted to the ICU. METHODS: In this retrospective registry-based cohort study, we used data from the Australia and New Zealand Intensive Care Society Adult Patient (age ≥16 years) database to identify patients with advanced (solid and haematological cancer) and a documented Clinical Frailty scale (CFS) admitted to 166 Australian ICUs. Patients without metastatic cancer were excluded. We analysed the effect of frailty (CFS 5-8) on long-term survival, and how this effect changed in specific subgroups (cancer subtypes, age [<65 years or ≥65 years], and those who survived hospitalisation). Because estimates tend to cluster within centres and vary between them, we used Cox proportional hazards regression models with robust sandwich variance estimators to assess the effect of frailty on survival time up to 4 years after ICU admission between groups. FINDINGS: Between Jan 1, 2018, and March 31, 2022, 30 026 patients were eligible, and after exclusions 21 174 patients were included in the analysis; of these, 6806 (32·1%) had frailty, and 11 662 (55·1%) were male, 9489 (44·8%) were female, and 23 (0·1%) were intersex or self-reported indeterminate sex. The overall survival was lower for patients with frailty at 4 years compared with patients without frailty (29·5% vs 10·9%; p<0·0001). Frailty was associated with shorter 4-year survival times (adjusted hazard ratio 1·52 [95% CI 1·43-1·60]), and this effect was seen across all cancer subtypes. Frailty was associated with shorter survival times in patients younger than 65 years (1·66 [1·51-1·83]) and aged 65 years or older (1·40 [1·38-1·56]), but its effects were larger in patients younger than 65 years (pinteraction<0·0001). Frailty was also associated with shorter survival times in patients who survived hospitalisation (1·49 [1·40-1·59]). INTERPRETATION: In patients with metastatic cancer admitted to the ICU, frailty was associated with poorer long-term survival. Patients with frailty might benefit from a goal-concordant time-limited trial in the ICU and will need suitable post-intensive care supportive management. FUNDING: None.

来源:Lancet Healthy Longev,查看原文。版权归原作者所有。

引用

  1. Alamgeer M, Ling RR, Ueno R, et al. Frailty and long-term survival among patients in Australian intensive care units with metastatic cancer (FRAIL-CANCER study): a retrospective registry-based cohort study. Lancet Healthy Longev. 2023. PMID: 38042160. doi:10.1016/S2666-7568(23)00209-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。